TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.